COVID-19 Related Lockdown Effects On Chronic Diseases
COVID-19 Related Lockdown Effects On Chronic Diseases
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal
 situation of physical and social isolation. Our hypothesis is that in patients with chronic
 diseases, confinement leads to changes in health behaviours, adherence to pharmacological
 treatment, lifestyle rules and increased psychosocial stress with an increased risk of
 deterioration in their health status in the short, medium and long term.

 Some messages about the additional risk/danger associated with taking certain drugs in the
 event of COVID disease have been widely disseminated in the media since March 17, 2020, the
 date on which containment began in France. This is the case, for example, for
 corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme
 inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major
 classes of drugs are widely prescribed in patients with chronic diseases, diseases
 specifically selected in our study (corticosteroids: haematological malignancies, multiple
 sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery
 disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a
 secondary prophylaxis after a myocardial infarction can be stopped by some patients who
 consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this
 antiplatelet agent, which must be taken for life after an infarction, exposes the patient to
 a major risk of a new cardiovascular event.

 The current difficulty of access to care due to travel restrictions (a theoretical limit in
 the context of French confinement but a priori very real), the impossibility of consulting
 overloaded doctors, or the cancellation of medical appointments, medical and surgical
 procedures due to the reorganization of our hospital and private health system to better
 manage COVID-19 patients also increases the risk of worsening the health status of chronic
 patients who by definition require regular medical monitoring.

 Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease,
 heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic
 respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health
 impact of the containment related to the COVID-19 pandemic.
Inclusion Criteria:

 -  patients with one of the following chronic diseases: chronic coronary syndrome, heart
 failure, multiple sclerosis, Horton's disease, AMD, malignant haemopathy, chronic
 respiratory failure (idiopathic fibrosis, PAH, haemophilia) and already registered in
 one of the 8 Burgundian registries/cohorts.

 Exclusion Criteria:

 -  deceased patient, patient cannot be reached after >3 telephone calls, patient or
 caregiver does not speak French to carry out telephone interviews